TORONTO, Ontario and HOUSTON — December 9, 2025 — Leads & Copy — Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF) will host a live webinar on December 10, 2025, at 8:30 a.m. Eastern Time to present updated clinical data from the ABILITY-1 Phase 1/2 Study, which evaluates MDNA11 as a monotherapy and in combination with pembrolizumab.
The webinar will feature Medicenna’s management team and the presenting Principal Investigator along with commentary from key opinion leaders to discuss the updated data, which will be presented at the ESMO Immuno-Oncology Congress 2025 on December 10th.
Presenters will include Dr. Fahar Merchant, President and CEO of Medicenna; Dr. Arash Yavari, Director of Clinical Strategy; and Dr. André Mansinho, Assistant Professor at the Faculty of Medicine, University of Lisbon, who is the presenting Principal Investigator. A live Q&A session will follow the presentation.
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. MDNA11, Medicenna’s long-acting IL-2 Superkine, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells.
The company’s first-in-class targeted PD-1 x IL-2 bispecific, MDNA113, is in development for solid tumors and was designed using Medicenna’s proprietary BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) platforms.
Bizaxofusp (formerly MDNA55), Medicenna’s IL-4 Empowered Superkine, has been studied in five clinical trials involving over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. It has also obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.
Participants can register for the webinar through the link provided in the original release. A replay will be available on Medicenna’s website following the event.
Investor/Media Contact:
Shushu Feng
Investor Relations, Medicenna Therapeutics
(416) 964-5442
ir@medicenna.com
Source: Medicenna Therapeutics
